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Abstract
FBP1, fructose-1,6-bisphosphatase-1, a gluconeogenesis regulatory enzyme, catalyzes the hydrolysis of fructose 1,6-
bisphosphate to fructose 6-phosphate and inorganic phosphate. The mechanism that it functions to antagonize glycolysis
and was epigenetically inactivated through NF-kappaB pathway in gastric cancer has been reported. However, its role in the
liver carcinogenesis still remains unknown. Here, we investigated the expression and DNA methylation of FBP1 in primary
HCC and colon tumor. FBP1 was lowly expressed in 80% (8/10) human hepatocellular carcinoma, 66.7% (6/9) liver cancer cell
lines and 100% (6/6) colon cancer cell lines, but was higher in paired adjacent non-tumor tissues and immortalized normal
cell lines, which was well correlated with its promoter methylation status. Methylation was further detected in primary HCCs,
gastric and colon tumor tissues, but none or occasionally in paired adjacent non-tumor tissues. Detailed methylation
analysis of 29 CpG sites at a 327-bp promoter region by bisulfite genomic sequencing confirmed its methylation. FBP1
silencing could be reversed by chemical demethylation treatment with 5-aza-29-deoxycytidine (Aza), indicating direct
epigenetic silencing. Restoring FBP1 expression in low expressed cells significantly inhibited cell growth and colony
formation ability through the induction of G2-M phase cell cycle arrest. Moreover, the observed effects coincided with an
increase in reactive oxygen species (ROS) generation. In summary, epigenetic inactivation of FBP1 is also common in human
liver and colon cancer. FBP1 appears to be a functional tumor suppressor involved in the liver and colon carcinogenesis.
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Introduction
Hepatocellular carcinoma (HCC) remains the third leading
cause of cancer death worldwide and the second most common
malignancy in China. The molecular pathogenesis of HCC
remains largely unknown. It has been hypothesized that
development and progression of HCC are the consequence of
cumulative genetic and epigenetic events. CpG hypermethylation
acts as an alternative mechanism to gene inactivation, and it is
now recognized as an important mechanism during tumor
initiation and progression, including liver cancer [1,2]. It is
important and intriguing to identify new genes silenced by
promoter hypermethylation in liver cancer because aberrant
tumor suppressor gene (TSG) hypermethylation is both a
mechanism and a biomarker for tumorigenesis [3].
FBP1, fructose-1,6-bisphosphatase 1, a gluconeogenesis regula-
tory enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate
to fructose 6-phosphate and inorganic phosphate. Fructose-1,6-
diphosphatase deficiency is associated with hypoglycemia and
metabolic acidosis. It was reported [4] that FBP1 which functions
to antagonize glycolysis was downregulated through NF-kappaB
pathway in Ras-transformed NIH3T3 cells. NF-kappaB functions
downstream of Ras to promote epigenetic downregulation of
FBP1. Inhibition of NF-kappaB reversed promoter methylation-
mediated FBP1 downregulation. Moreover, promoter methylation
of FBP1 was relevant to gastric carcinogenesis, for example,
gender, TNM stages and survival rate were significantly associated
with FBP1 promoter methylation. Besides, it was studied [5] that
FBP1 promoter methylation contributes to the decreased expres-
sion of FBPase in breast cancer. When non-malignant and
malignant tissue samples from the same patient were compared a
correlation between an increase of FBPase promoter methylation
and a decrease of FBPase mRNA levels was observed. However,
no findings are shown for FBP1 epigenetic inactivation in the liver
carcinogenesis.
Reactive oxygen species (ROS), chemically-reactive molecules
containing oxygen, including oxygen ions and peroxides, are the
key mediators of cellular oxidative stress and redox dysregulation
involved in cancer initiation and progression. It is now widely
accepted that constitutively elevated levels of cellular oxidative
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signaling in cancer cells are involved in the carcinogenesis.
Paradoxically, apart from being involved in proliferative, anti-
apoptotic, metastatic, and angiogenic signaling, ROS may also
exert cytotoxic and proapoptotic functions that would limit
tumorigenicity and malignant progression [6,7]. FBP1 is a
multifunctional protein that is, in addition to its function in
gluconeogenesis, involved in ROS production after treatment with
MMS or in chronologically aged cells [8]. In the absence of FBP1
cells survive MMS treatment better and even proliferate after
long-term treatment. This could be the result of reduced
production of ROS observed in the DFBP1 mutant in response
to the alkylating agent methylmethane sulfonate (MMS) treatment
and aging. Lack of FBP1 improved surviving of aged cells in full
medium and resulted in a delayed induction of ROS production.
Overexpression of FBP1 reduced the ability to form colonies even
of untreated cultures, shortened life span and increased the
induction of the RNR2 promoter after MMS treatment.
Here, we demonstrated that FBP1 underwent promoter CpG
hypermethylation-associated silencing in human liver and colon
cancer. The analysis of liver and colon cancer cell lines and tissues
showed that FBP1 hypermethylation was a common event in
human liver and colon cancer. We also showed that FBP1
functions as a TSG to suppress cancer cell growth through the
induction of G2-M phase cell cycle arrest and an increase in ROS
generation levels. Epigenetic changes in cellular redox homeostasis
and ROS levels will affect viability through redox modulation of
the mitochondrial permeability transition pore opening leading to
cytochrome C release, apoptosome assembly and activation of
executioner caspases, which is supportive for ROS-directed cancer
chemotherapeutics.
Materials and Methods
Cancer Cell Lines, Primary Tumor Tissues and RNA/DNA
Extraction
Nine human liver cancer cell lines (HepG2, Hep3B, Huh7,
HCC-LM3, BEL-7402, SMMC-7721, Sk-Hep1, MHCC-97H
and MHCC-97L) were used for HCCs analysis. One immortalized
normal human liver cell lines L02 was used as ‘‘normal’’ controls
for HCCs analysis. Six human colon cancer cell lines (HT29,
SW480, SW620, HCT116, LoVo and RKO) were used for colon
cancer analysis and human normal adult colon tissues were used as
‘‘normal’’ controls. All of the cell lines were obtained from
American Type Culture Collection (ATCC, Manassas, Va., USA).
Unless specifically indicated, cells were cultured in DMEM
medium (Invitrogen, Carlsbad, Calif., USA) supplemented with
10% fetal bovine serum at 37uC with 5% CO2 and 95% humidity.
For pharmacological demethylation, cells were treated with 5 uM
5-aza-29-deoxycytidine (Aza) (Sigma, St. Louis, Mo., USA) for 3
consecutive days. Culture medium was changed every 24 hours.
An equivalent concentration of vehicle (DMSO) was used as the
control.
Primary HCCs were obtained from liver cancer patients in
Huashan Hospital at the time of surgery; matched non-tumor
samples from liver cancer patients were also obtained at least 2 cm
distant from the tumor. Non-tumor portions were trimmed off
from the frozen tumor blocks and the selected tumor areas had
more than 80% tumor cells as confirmed by histology. Human
gastric, colon tumor tissues and normal adult colon tissues were
provided by Chinese Medicine Hospital of Zhejiang. All patients
gave informed consent for obtaining the study specimens.
Total RNA and genomic DNA were extracted using Trizol
reagent (Invitrogen) according to the manufacturer’s instructions.
Total RNA and DNA concentrations were quantified by
NanoDrop 1000 (Nanodrop, Wilmington, Del., USA).
Real-Time RT-PCR
A reverse transcription reaction was performed using 1 ug of
total RNA with High Capacity cDNA Reverse Transcription kit
(Applied Biosystems, Foster City, Calif., USA). The mRNA
expression levels of FBP1 were determined by Real-Time RT-
PCR using SYBR Green Master Mix Kit and ABI 7500 Real-
Time RT-PCR System (Applied Biosystems, Foster City, Calif.,
USA). Glyceraldehyde-3- phosphate dehydrogenase (GAPDH)
was used as an internal control of RNA integrity. Real-Time RT-
PCR was performed in triplicate. Primers used for FBP1 were:
FBP1-F 59-ATCCCCTTGATGGATCTTCC-39 and FBP1-R 59-
TCCAGCATGAAGCAGTTGAC-39 (208 bp product).
Bisulfite Treatment of DNA and Methylation-Specific PCR
Genomic DNA was bisulfite-treated with Zymo DNA Modifi-
cation Kit (Zymo Research, Orange, Calif., USA) according to the
protocol provided. Methylation-specific PCR (MSP) was carried
out for 40 cycles with annealing temperature at 60uC. Methyla-
tion-specific primers were: FBP1-MF 59-TGAAGATTTAAG-
TAGGCGGAGTC-39 and FBP1-MR 59-ATAAACACTAACCG
CAAATACGAA-39, and unmethylation-specific primers were:
FBP1-UF 59-GAAGATTTAAGTA GGTGGA GTTGTG-39 and
FBP1-UR 59-CTAACAAAAAAACTAACAAACCAAC-39.
Bisulfite Genomic Sequencing
Bisulfite-treated genomic DNA was amplified using bisulfite
genomic sequencing (BGS) primers, FBP1-BF: 59-TGATTTTG-
GAGGAAATAGTTATAGTTTTT-39 and FBP1-BR: 59-TAA-
TACAACTAAACCAAACCAAAC-39. PCR products were puri-
fied with Illustra GFX
TMPCR and gel band purification kit (GE
Healthcare Life Science, Uppsala, Sweden) and cloned into
pCR4-TOPO vector for sequencing (Invitrogen). At least four
colonies were randomly chosen for plasmid extraction and
sequencing analysis using the ABI PRISM BigDye Terminator
Cycle Sequencing Kit in the ABI 3100 sequencer (Applied
Biosystems).
Construction of FBP1 Expressing Vector
The FBP1 expressing vector was constructed by cloning of the
full-length FBP1 open reading frame into mammalian expression
vector pcDNA3.1. The full-length FBP1 open reading frame was
amplified from normal stomach cDNA using high-fidelity PFU
DNA polymerase (Invitrogen). The primers used for cloning were
FBP1-CF: 59-CGGAATTCCGATGGCTGACCAGGCGCCC-
TTCGA-39 and FBP1-CR: 59-GCAAGCTTCCTGGGCAGAG-
TGCTTCTCATACACC-39 accomp- anied with double enzyme
cutting sites ECoRI and Hind III. The sequence and orientation of
the insert were confirmed by DNA sequencing.
Colony Formation Assay
Human liver cancer cells transiently transfected with pcDNA3.1
empty vector or pcDNA-FBP1 expressing vector were used for the
monolayer colony formation assay to evaluate cellular growth in
vitro. Cells were cultured overnight in a 12-well plate (5610
5 cells/
well) and transfected with pcDNA3.1 empty vector or pcDNA-
FBP1 expressing vector using FuGENE 6 (Roche Applied Science,
Mannheim, Germany). Forty-eight hours later, the transfectants
were replated in triplicate and cultured for 10,15 days in
complete DMEM medium containing G418 (400 ug/ml). Surviv-
ing colonies were stained with Gentian Violet after methanol
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experiments were repeated three times.
Cell Growth Assay
Cells growth were determined by a non-radioactive prolifera-
tion assay based on the ability of metabolically active cells to
convert 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2
-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI,
USA) into formazan. Surviving cells after G418 selection were
replated into a 96-well plate with different cell number and
cultured in complete DMEM medium containing G418 (400 ug/
ml) for another 72 hours. The quantity of formazan was measured
as the above. The quantity of formazan was measured at 490 nm
absorbance after one hour incubation with CellTiter 96 AQueous
One Solution Reagent following instructions provided.
Cell Cycle Analysis and Determination of ROS Production
Surviving cells after G418 selection were trypsinized, washed in
phosphate-buffered saline, and fixed in ice-cold 70% ethanol–
phosphate-buffered saline. After washing out ethanol, the fixed
cells were treated with 0.01% RNase (10 mg/ml, Sigma, St. Louis,
MO, USA) for 10 min at 37uC and then stained with 0.05%
propidium iodide for 20 min at 4uC in dark. The cell cycle
distribution was determined using a FACScan flow cytometry
(Becton Dickinson, Mountain View, CA, USA) and analyzed with
Modfit software (Phoenix, San Diego, CA, USA). Cells undergoing
apoptosis were detected as sub-G1 population because of loss of
fragmented DNA.
ROS levels were measured by using 29-79-Dichlorodihydro-
fluorescein diacetate (DCFH-DA) (Invitrogen) in a flow cytometry
assay as described [9].
Statistic Analysis
The results were expressed as mean 6 standard deviation (SD).
Student t test was used to compare the differences of FBP1
expression on the effect of colony formation and cell proliferation.
All statistical calculations were done using SPSS version 11.0 for
windows (SPSS, Inc., Chicago, IL). Value of P,0.05 was taken as
statistical significance.
Results
Downregulation of FBP1 in Human Liver and other
Digestive Cancers
The expression of FBP1 was dramatically downregulated in
66.7% (6/9) human liver cancer cell lines including HepG2, BEL-
7402, SMMC-7721, Sk-Hep1, MHCC-97H and MHCC-97L
(Figure 1A) when compared to human normal liver cells Lo2.
Similarly, downregualtion of FBP1 was also found in 100% (6/6)
human colon cancer cell lines including HT29, SW480, SW620,
HCT116, LoVo and RKO (Figure 1A) when compared to human
normal adult colon tissue. In order to know whether downregu-
lation of FBP1 should be attributed to DNA methylation, the
expression of FBP1 in human liver and colon cancer cell lines
before and after Aza treatment were determined by Real-Time
RT-PCR. The expression of FBP1 was significantly upregulated in
Figure 1. Pharmacological demethylation reversed FBP1 downregulation in human liver and other digestive cancers. (A) FBP1
expression in human liver and colon cancer cell lines and normal controls were determined by Real-Time RT-PCR. GAPDH was used to normalize the
template amount. (B) Relative FBP1 expression before and after Aza treatment were determined by Real-Time RT-PCR. GAPDH was used to normalize
the template amount. It was shown as average fold changes 6 SD.
doi:10.1371/journal.pone.0025564.g001
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MHCC-97H and MHCC-97L (6/9, 66.7%) after Aza treatment
(Figure 1B) and also in colon cancer cell lines HT29, SW620,
LoVo and RKO (4/6, 66.7%) (Figure 1B), indicating that FBP1 is
likely downregulated through promoter hypermethylation in
human liver and colon cancer.
Methylation of FBP1 Promoter in Human Liver and Colon
Cancers
Indeed one typical CpG Islands (CGI) were found around FBP1
exon 1 using the following criteria: GC content .55%, Obs CpG/
Exp CpG .0.65, and length .500 bp (Figure 2A). The
methylation status of this CGI in human liver and colon cancer
cells was determined by MSP. As shown in Figure 2B, methylation
of FBP1 promoter was readily detected in liver cancer cell lines
HepG2, HuH7, HCC-LM3, BEL-7402, SMMC-7721, Sk-Hep1,
MHCC-97H and MHCC-97L, and human colon cancer cell lines
HT29, SW480, SW620, HCT116, LoVo and RKO. Besides, BGS
also revealed that FBP1 promoter was heavily methylated in
HepG2, Huh7, BEL-7402 cells and 8T tumor tissue, and no
methylation was dedtected in 8N adjacent non-tumor tissue
(Figure 2C).
Downregulation and Promoter Hypermethylation of
FBP1 in Human Primary Tumor Tissues
To further confirm the relevance of FBP1 promoter CGI
hypermethylation in mediating its silencing in human liver, gastric
and colon cancer, FBP1 expression and promoter methylation in
primary hepatocellular carcinoma, gastric and colon tumor tissues
and adjacent non-tumor tissues were analyzed by Real-Time RT-
PCR and MSP, respectively. FBP1 expression was significantly
downregulated in 80% (8/10) human liver tumor tissues, 100%
(5/5) in gastric and 80% (4/5) colon tumor tissues (Figure 3A)
when compared with adjacent non-tumor tissues. In addition,
promoter methylation was frequently detected by using MSP in
tumor samples but not non-tumor tissues (Figure 3B), indicating
that downregulation of FBP1 was involved in the carcinogenesis of
human liver and other digestive cancers.
FBP1 Overexpression Reduced Cancer Cell Colony
Formation Abilities and Inhibited the Growth of Liver and
Colon Cancer Cells
The effect of exogenous FBP1 expression on the growth of
human liver cancer cells was investigated by a monolayer colony
formation assay. To further investigate the potential role of FBP1
Figure 2. Methylation of FBP1 promoter in human liver and colon cancer. (A) Schematic structure of the FBP1 CGI, with the exon 1 and MSP
and BGS region indicated. Each short vertical line represents one CpG site. The position of MSP primers were marked as arrows. The methylation
status of the FBP1 CGI was analyzed by MSP (B) and BGS (C). MSP=Methylation-specific PCR; USP=Unmethylation-specific PCR. For BGS in (C), each
circle indicates one CpG site and circles filled in black represent methylated CpG sites. One row of circles represents a single colony.
doi:10.1371/journal.pone.0025564.g002
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cancer SW480 was transfected with pcDNA-FBP1 expressing
vector and the cell colony formation ability was examined under
the selection of G418. Compared with control cells transfected
with empty vector pcDNA3.1, cancer cells transfected with
pcDNA-FBP1 expressing vector showed decreased colony forma-
tion ability (Figure 4B). These data suggest that FBP1 may play a
role in tumor suppression. Besides, FBP1 stable expression levels in
those cells including SW480 and SMMC-7721 was also confirmed
by Real-Time RT-PCR as shown in Figure 4A.
When pcDNA-FBP1 was transfected into SW480 and SMMC-
7721 cells, the growth inhibitory function of FBP1 in these cells
was confirmed by MTS cell growth assay. PcDNA-FBP1
expressing vector was transfected into these cells, the growth
speed of human liver and colon cancer cells after FBP1
overexpression was dramatically reduced in MTT cell growth
assay (p,0.05; Figure 4C), showing a growth-suppressive effect of
FBP1 on cancer cells.
Ectopic Expression of FBP1 Induced G2-M Phase Arrest
To determine the molecular mechanism by which FBP1
suppressed colony formation and cell proliferation, we investigated
the effect of FBP1 on cell cycle distribution. After propidium
iodide staining, fluorescence-activated cell sorting analysis of FBP1
overexpressed SW480 and SMMC-7721 cells revealed an increase
in the number of G2-M phase cells and a decrease in the number
of S phase cells (Figure 5A and 5B).
FBP1 Overexpression Increased Intracellular ROS
Production
The ROS levels were measured in cancer cells untransfected and
transfected with pcDNA-FBP1 expressing vector. Exogenous FBP1
expression clearly increased intracellular ROS levels in SMMC-
7721 and SW480 cells (Figure 6A and 6B). Therefore, FBP1 could
increase ROS production which exert cytotoxic and proapoptotic
functions and limit tumorigenicity and malignant progression.
Figure 3. FBP1 gene was downregulated and hypermethylated in primary tumor tissues. (A) The expression of FBP1 in liver, gastric and
colon tumor tissues and adjacent non-tumor tissues were determined by Real-Time RT-PCR. 1,10 T/N: liver cancer, 11–15 T/N: gastric cancer, 16,20
T/N: colon cancer. (B) The methylation status of FBP1 promoter in primary liver, gastric and colon tumor tissues and adjacent non-tumor tissues was
detected by MSP. Representative results were shown. 1,3 T/N: liver cancer, 4,5 T/N: colon cancer, 6,9 T/N: gastric cancer. ‘‘T’’ indicates tumor
tissues and ‘‘N’’ represents adjacent non-tumor tissues.
doi:10.1371/journal.pone.0025564.g003
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More and more novel tumor suppressor genes have been found
to be inactivated by promoter hypermethylation. Promoter
methylation was thus proposed as an important marker for the
identification of novel tumor suppressor genes. In the current
study, we identified that FBP1 was frequently down-regulated in
66.7% HCC cell lines and 100% colon cancer cell lines
(Figure 1A), and in 80% primary HCCs, 100% gastric tumors
and 80% colon tumors (Figure 3A). Hypermethylation was further
detected in 66.7% HCC cell lines and 100% colon cancer cell lines
(Figure 2B), and also in primary tumor tissues (Figure 3B). In
contrast, FBP1 hypermethylation was hardly detected in normal
liver cell lines and occasionally in paired adjacent non-tumor
tissues, suggesting an important role of FBP1 in the pathogenesis of
liver and other digestive cancers. We further demonstrated that
treatment with the demethylation reagent Aza upregulated FBP1
expression in lowly expressed cancer cells (Figure 1B) and the
methylation status was verified by genomic sequencing, indicating
that DNA hypermethylation mediated FBP1 inactivation.
In cancer, the dynamics of genetic and epigenetic gene silencing
are very different. Somatic genetic mutation leads to a block in the
production of functional protein from the mutant allele. If a
selective advantage is conferred to the cell, the cells expand
clonally to give rise to a tumor in which all cells lack the capacity
to produce protein. In contrast, epigenetically mediated gene
silencing occurs gradually. It begins with a subtle decrease in
transcription, fostering a decrease in protection of the CpG island
from the spread of flanking heterochromatin and methylation into
the island. This loss results in gradual increases of individual CpG
sites, which vary between copies of the same gene in different cells.
For example, higher level of FBP1 was detected in Huh7 and
HCC-LM3 cells with high methylation level in the promoter
region (Figure 1A and 2B). Although promoter methylation
frequently inactivated FBP1 in human liver and colon cancer cell
lines, we cannot exclude the involvement of other mechanisms
responsible for the FBP1 downregulation, such as defects in
histone remodeling. For instance, in Hep3B, Huh7, HCC-LM3,
SW480 and HCT116 cells, FBP1 promoter failed to be fully
upregulated after Aza treatment (Figure 1B).
In addition, to serve as a new marker to define novel tumor
suppressor genes, promoter hypermethylation can also be used as
a sensitive marker for cancer diagnosis and prognosis prediction
[10,11]. Unfortunately, for lack of large numbers of tumor tissues,
Figure 4. FBP1 overexpression reduced liver cancer cell colony formation abilities. (A) FBP1 expression level in the transfected SW480 and
SMMC-7721 cells was confirmed by Real-Time RT-PCR. (B) The effect of ectopic FBP1 expression on liver cancer cell growth was investigated by the
monolayer colony formation assay. The scanned colony formation in six-well plates was shown in the panel.. (C) The growth of liver and colon cancer
cell lines (SW480 and SMMC-7721) with and without FBP1 expression was determined with MTS cell growth assay. Stable expression of FBP1
suppressed the growth of liver and colon cancer cells. The results were shown as values of mean 6 SD. P values were calculated using Student’s t-test
(* p,0.05).
doi:10.1371/journal.pone.0025564.g004
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analyze its association with clinical characteristics, such as age,
gender, tumor grade and survival rate. We had to determine FBP1
expression and methylation status in only 10 pairs of primary
HCCs, 5 pairs of gastric tumor tissues and 5 pairs of colon tumor
tissues (Figure 3), suggesting that FBP1 functions as a novel tumor
suppressor candidate downregulated through promoter hyper-
methylation in liver and colon cancer. This is also the first report
to show that FBP1 is epigenetically silenced in human liver and
colon carcinogenesis. Once FBP1 promoter methylation was
detected at a high frequency in primary carcinoma tissues but not
non-tumor normal gastric tissues, FBP1 promoter methylation
may be a potential biomarker for cancer diagnosis.
As is shown in Figure 4, restoration of FBP1 expression
markedly suppressed cancer cells growth. However, the underlying
molecular mechanism responsible for FBP1 functions as a tumor
suppressor remains unknown. It has been verified [4] that FBP1
functions to antagonize glycolysis. As is well known, cancer cells
have a higher rate of aerobic glycolysis, but not oxidative
phosphorylation. Fructose-1,6-bisphosphate is one of the most
important intermediates in glycolysis and its level is mainly
controlled by fructose-6-phosphate kinase and fructose-1,6-
bisphosphatase. It was found that the production of lactate after
FBP1 expression was significantly reduced, demonstrating the
suppression of aerobic glycolysis by FBP1. Besides, cell cycle
checkpoints are important control mechanisms that ensure the
proper execution of cell cycle events. The growth suppression
induced by ectopic FBP1 expression seems to be caused by cell
cycle arrest since the numbers of cells with cell cycle blockage (G2-
M phase arrest) were increased after FBP1 re-expression (Figure 5).
For a long time, ROS were considered oncogenic since it was
implicated in cancer progression and metastasis. Persistent
oxidative stress has been associated with breast carcinoma and
many epithelial cancers such as colon and neck cancers [12].
However, numerous studies have demonstrated the causative
involvement of ROS formation in the mediation of cancer cell
apoptosis induced by various standard chemotherapeutic agents
including paclitaxel, cisplatin, bortezomib and etoposide. Remark-
ably, it has been demonstrated that cisplatin apoptogenicity
depends on formation of ROS and occurs independent of nuclear
DNA damage, suggesting that apoptogenic oxidative stress is the
crucial mechanism of cisplatin-induced cancer cell death [13]. In
addition to causing cell cycle arrest at the S phase, importantly in
this study, the growth inhibitory effect of FBP1 as a tumor
suppressor may also be mediated through enhancing the
production of intracellular ROS (Figure 6). Our findings were
Figure 5. Effect of FBP1 on the cell cycle of liver and colon cancer cell line. The cell cycle distribution of liver and colon cancer cell line
(SW480 and SMMC-7721) with and without FBP1 expression was evaluated by flow cytometry analysis. (A) and (B) Representative fluorescence -
activated cell sorting analysis of cancer cells transfected with or without FBP1.
doi:10.1371/journal.pone.0025564.g005
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1,6-bisphosphatase mediates cellular responses to DNA damage
and aging in Saccharomyces cerevisiae. But how ROS exert
cytotoxic and proapoptotic functions that would limit tumorige-
nicity and malignant progression, it was proposed that changes in
cellular redox homeostasis and ROS levels will affect viability
through redox modulation of the mitochondrial permeability
transition pore opening leading to cytochrome C release,
apoptosome assembly, and activation of executioner caspases, if
cellular ROS levels reach a certain threshold incompatible with
cellular survival [7,14].
In summary, we found that FBP1 is frequently reduced by
promoter hypermethylation in most liver and colon cancer cell
lines and primary tumor tissues. Our results suggested that
epigenetic inactivation of FBP1 was an important factor in human
liver and colon carcinogenesis. We also demonstrated that
promoter hypermethylation-mediated silencing of FBP1 could be
reversed by pharmacologic demethylation and restoration of FBP1
suppressed tumor cell growth through inducing G2-M phase cell
cycle arrest and an increase in ROS generation. Therefore, it will
be valuable to explore the possible application of FBP1 as a
molecular marker for the detection and treatment of these
malignancies.
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